Catalog No.

CS974226

Species reactivity

Human

Applications

Research Grade Biosimilar

Isotype

Fusion - [CD80 (B7-1, CD28LG1) fragment (1-107)]2 - IGHG1 Fc (Fragment constant)

Expression system

Mammalian Cells

Target

B7-H1, Programmed cell death 1 ligand 1, PDCD1 ligand 1, PDCD1L1, B7 homolog 1, PDCD1LG1, PDL1, hPD-L1, Programmed death ligand 1, B7H1, PD-L1, CD274, CD28, TP44, T-cell-specific surface glycoprotein CD28, CD152, Cytotoxic T-lymphocyte protein 4, CTLA-4, CTLA4, Cytotoxic T-lymphocyte-associated antigen 4

Concentration

1mg/ml

Endotoxin level

Please contact the lab for this information.

Purity

>95% purity as determined by SDS-PAGE.

Purification

Protein A/G, purified from cell culture supernatant.

Accession

Q9NZQ7 & P10747 & P16410

Form

Liquid

Storage buffer

0.01M PBS,pH7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12months. For long-term storage, store at -1204°C.

Alternate Names

ALPN-202,CD80vIgD-Fc,CAS:2307144-64-3

Background

Davoceticept (ALPN-202; CD80 vIgD-Fc) is a variant CD80 vIgD-Fc fusion protein targeting CTLA-4 and PD-L1. Davoceticept consists of the (1-107) fragment of CD80 linked to IGHG1 Fc via a peptidyl linker. The expression system of Davoceticept is usually CHO (Chinese Hamster Ovary) cells.

Note

For research use only. Not for use in clinical or therapeutic applications.